Abivax Joins the Nasdaq Biotechnology Index
Biotechnology company Abivax has announced its inclusion in the Nasdaq Biotechnology Index, effective as of market opening on December 22, 2025.
Inclusion in the Index
Abivax will join the Nasdaq Biotechnology Index starting Monday, December 22, 2025, according to a press release issued on December 18. The NBI tracks the performance of a set of companies listed on the Nasdaq Stock Market and classified as biotechnology or pharmaceutical companies according to the Industry Classification Benchmark. Inclusion in this index implies meeting eligibility criteria including minimum market capitalization, average daily trading volume, and tenure as a listed company. The NBI is subject to an annual review in December, and its calculation methodology is based on a modified market capitalization weighting.
A Significant Milestone
Didier Blondel, CFO of Abivax, described this inclusion as a significant milestone for the company, the press release states. According to him, this entry into the index reflects the progress made by the group, particularly in the development of obefazimod, its flagship drug candidate. It also demonstrates increased visibility and perception of Abivax within the global biotechnology community, the company notes.
About Abivax
Abivax is a clinical-stage biotechnology company based in France and the United States, developing therapies aimed at stabilizing the immune response in patients with chronic inflammatory diseases. Its main drug candidate, obefazimod, is currently undergoing phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. The company has notably conducted the phase 3 ABTECT Induction trials for this indication, according to the press release. The company is listed on Euronext Paris and on the Nasdaq.
